Fate Therapeutics to Present at Upcoming Investor Conferences
August 31 2016 - 4:01PM
Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company
dedicated to the development of programmed cellular immunotherapies
for cancer and immune disorders, today announced that Scott
Wolchko, President and Chief Executive Officer, will be presenting
at two upcoming investor conferences in September:
- 2016 Wells Fargo Healthcare Conference at 1:45
p.m. ET on Wednesday, September 7, 2016 in Boston.
- Rodman & Renshaw 18th Annual Global Investment
Conference at 11:15 a.m. ET on Tuesday, September 13, 2016
in New York City.
Live webcasts of the presentations will be available through the
investor relations section of the Company's website at
www.fatetherapeutics.com. Following the live webcasts, archived
replays of each presentation will be available on the Company's
website for 30 days after the respective conference.
About Fate Therapeutics, Inc.Fate Therapeutics
is a biopharmaceutical company dedicated to the development of
programmed cellular immunotherapies for cancer and immune
disorders. The Company’s cell therapy pipeline is comprised of
immuno-oncology programs, including off-the-shelf NK- and T-cell
cancer immunotherapies derived from engineered induced pluripotent
cells, and immuno-regulatory programs, including hematopoietic cell
immunotherapies for protecting the immune system of patients
undergoing hematopoietic cell transplantation and for regulating
autoimmunity. Its adoptive cell therapy programs are based on the
Company’s novel ex vivo cell programming approach, which it applies
to modulate the therapeutic function and direct the fate of immune
cells. Fate Therapeutics is headquartered in San Diego, CA. For
more information, please visit www.fatetherapeutics.com.
Contact:
Jesse Baumgartner
Stern Investor Relations, Inc.
212.362.1200
jesse@sternir.com
Fate Therapeutics (NASDAQ:FATE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Fate Therapeutics (NASDAQ:FATE)
Historical Stock Chart
From Apr 2023 to Apr 2024